Paul Carter - Mallinckrodt Plc Independent Director

Director

Mr. Paul Rutherford Carter was appointed as Independent Director of the Company. He has held a variety of leadership roles in the biopharmaceutical industry, serving as executive vice president, commercial operations of Gilead Sciences, Inc. from 2014 to 2016, and senior vice president and head, international commercial operations from 2006 to 2014. Prior to joining Gilead, he served as regional vice president, China and Hong Kong at GlaxoSmithKline plc, and also held roles at Sterling Health Ltd. which was acquired by GSK in 1995, Bovis International and Arthur Andersen and Company. Mr. Carter also serves as a healthcare advisor to a number of biotechnology companies and is on the Boards of Alder Biopharmaceuticals, Inc., and Hutchison China MediTech Ltd since 2018.
Age 58
Tenure 7 years
Phone353 1 696 0000
Webhttps://www.mallinckrodt.com
Carter is a fellow of the Chartered Institute of Management Accountants, and holds a BA Honours degree in Business Studies from the University of West Londonin the U.K.

Mallinckrodt Plc Management Efficiency

Mallinckrodt Plc's management efficiency ratios could be used to measure how well Mallinckrodt Plc manages its routine affairs as well as how well it operates its assets and liabilities.
Mallinckrodt Plc has 3.07 B in debt with debt to equity (D/E) ratio of 1.44, which is OK given its current industry classification. Mallinckrodt Plc has a current ratio of 2.92, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Mallinckrodt to invest in growth at high rates of return.

Similar Executives

Found 7 records

DIRECTOR Age

Adam SzwerasAurora Cannabis
48
Norma BeauchampAurora Cannabis
59
David LazzaratoCanopy Growth Corp
64
Margaret AtkinsAurora Cannabis
63
Tyler BurnsCanopy Growth Corp
N/A
Frank FallwellSNDL Inc
N/A
Jason DyckAurora Cannabis
N/A
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. The company was founded in 1867 and is based in Dublin, Ireland. Mallinckrodt Plc operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on AMEX Exchange. It employs 2778 people. Mallinckrodt Plc (MNK) is traded on NYSE MKT Exchange in USA and employs 2,673 people.

Management Performance

Mallinckrodt Plc Leadership Team

Elected by the shareholders, the Mallinckrodt Plc's board of directors comprises two types of representatives: Mallinckrodt Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mallinckrodt. The board's role is to monitor Mallinckrodt Plc's management team and ensure that shareholders' interests are well served. Mallinckrodt Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mallinckrodt Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
CPA CPA, Global Officer
David Norton, Independent Director
Hugh ONeill, Executive Vice President and President, Autoimmune and Rare Diseases
Steven Romano, Executive Vice President and Chief Scientific Officer
Sigurdur Olafsson, Pres CEO
Mark Trudeau, CEO and President Director and Member of Portfolio Committee
Kneeland Youngblood, Independent Director
Bryan Reasons, Chief Financial Officer, Executive Vice President
Mark Casey, Executive Vice President and Chief Legal Officer
JoAnn Reed, Independent Director
J Carroll, Independent Director
Lisa French, Ex Officer
Kassie Harrold, Ex Officer
Jason Goodson, Exec Devel
Ian Watkins, Chief Human Resource Officer, Executive Vice President
Stephen Welch, Ex Generics
Henriette Nielsen, Ex Officer
Steven MD, Ex Officer
Angus Russell, Independent Non-Executive Chairman of the Board
Paul Carter, Independent Director
Carlos Paya, Independent Director
Anne Whitaker, Independent Director
Mark Tyndall, Chief VP

Mallinckrodt Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mallinckrodt Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Other Consideration for investing in Mallinckrodt Stock

If you are still planning to invest in Mallinckrodt Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Mallinckrodt Plc's history and understand the potential risks before investing.
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges